Abstract: A miR-520b sequence for inhibiting cancer growth and spread includes miR-520b sequence for inhibiting cancer growth and spread wherein the miR-520b sequence is 5?-AAAGUGCUUCCUUUUAGAGGGtt-3? of SEQ ID NO:2. A medicine for inhibiting cancer growth and spread includes a medicinal preparation including miR-520b substrate and medical agent wherein the miR-520b substrate is miR-520b sequence and has concentration of 50 ?M, and the miR-520b sequence is 5?-AAAGUGCUUCCUUUUAGAGGGtt-3? of SEQ ID NO:2.

Abstract: A method of using sequence of antagomiR for developing medicine for inhibiting oral cancer cells from spreading is provided with the steps of combining a sequence of antagomiR with active ingredient to prepare a medicine which is configured to administer to oral cavity grown with oral cancer cells so that both miR-196a and miR-196b of the sequence of antagomiR are configuring of developing medicine for curing oral cancer cells. The miR-196a has a sequence of 5?-UAGGUAGUUUCAUGUUGUUGGG-3?(SEQ.ID.NO.1). The miR-196b has a sequence of 5?-UAGGUAGUUUCCUGUUGUUGGG-3?(SEQ.ID.NO.2).

Abstract: A method of using miR-196a and miR-196b as biomarkers for oral cancer detection is provided with the steps of analyzing a sample from each of a plurality of human beings in terms of miR-196a and miR-196b wherein the miR-196a has a sequence of SEQ ID NO: 1 and miR-196b has a sequence of SEQ ID NO: 2; and detecting one of the human beings to have oral cancer if intensity of either miR-196a or miR-196b of the sample belonging to the human being is higher than a predetermined value.

Abstract: The present invention discloses a specific GRP78 expression-inhibition RNAi sequence, a medicine thereof and a method thereof, wherein an RNAi sequence 5?-AAGGATGGTTAATGATGCTGAGAA-3? [SEQ. ID NO: 1] complementary to GRP78 forms a special hair-pin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer.

Abstract: The present invention discloses a labeled molecule for prognosing the tumor grade of head and neck cancer and a method for the same, wherein a 78-kDA glucose regulated protein (GRP78) is adopted as a labeled molecule of head and neck cancer. GRP78 is much more overexpressed in head and neck cancer cells than in non-cancer cells. GRP78 also has relation with tumor size, tumor depth and tumor metastasis. Therefore, the present invention uses GRP78 overexpression as a reference for tumor grading of head and neck cancer.

Abstract: The present invention discloses a specific GRP78 expression-inhibition RNAi sequence, a medicine thereof and a method thereof, wherein an RNAi sequence 5?-AAGGATGGTTAATGATGCTGAGAA-3? complementary to GRP78 forms a special hair-pin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer.

Abstract: The present invention discloses a specific GRP78 expression-inhibition RNAi sequence, a medicine thereof and a method thereof, wherein an RNAi sequence 5?-AAGGATGGTTAATGATGCTGAGAA-3? complementary to GRP78 forms a special hair-pin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer.

Abstract: The present invention provide a method for analyzing the DSG3 overexpression in tumor tissues with clinical features of cancer cells to validate that overexpression is relates to size, depth and migration of tumor. Therefore, DSG3 overexpression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in Head Neck Cancer (HNC). Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective inhibition-specific DSG3 expression, and then inhibits cell growth, invasion and migration in HNC.

Abstract: The present invention discloses a specific GRP78 expression-inhibition RNAi sequence, a medicine thereof and a method thereof, wherein an RNAi sequence 5?-AAGGATGGTTAATGATGCTGAGAA-3? complementary to GRP78 forms a special hair-pin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer.

Abstract: The present invention provide a method for analyzing the DSG3 overexpression in tumor tissues with clinical features of cancer cells to validate that DSG3 overexpression is relates to size, depth and migration of tumor. Therefore, DSG3 overexpression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in Head Neck Cancer (HNC). Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective inhibition-specific DSG3 expression, and then inhibits cell growth, invasion and migration in HNC.

Abstract: The present invention provide a method for analyzing the DSG3 overexpression in tumor tissues with clinical features of cancer cells to validate that overexpression is relates to size, depth and migration of tumor. Therefore, DSG3 overexpression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in Head Neck Cancer (HNC). Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective inhibition-specific DSG3 expression, and then inhibits cell growth, invasion and migration in HNC.

Abstract: The present invention discloses a specific GRP78 expression-inhibition RNAi sequence, a medicine thereof and a method thereof, wherein an RNAi sequence 5?-AAGGATGGTTAATGATGCTGAGAA-3? complementary to GRP78 forms a special hair-pin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer.

Abstract: The present invention discloses a labeled molecule for prognosing the tumor grade of head neck cancer and a method for the same, wherein a 78-kDA glucose regulated protein (GRP78) is adopted as a labeled molecule of head neck cancer. GRP78 is much more overexpressed in head neck cancer cells than in non-cancer cells. GRP78 also has relation with tumor size, tumor depth and tumor metastasis. Therefore, the present invention uses GRP78 overexpression as a reference for tumor grading of head neck cancer.

Abstract: The present invention provide a method for analyzing the DSG3 overexpression in tumor tissues with clinical features of cancer cells to validate that DSG3 overexpression is relates to size, depth and migration of tumor. Therefore, DSG3 overexpression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in Head Neck Cancer (HNC). Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective inhibition-specific DSG3 expression, and then inhibits cell growth, invasion and migration in HNC.